Homepage Top Section2

Leqembi is a humanised anti-soluble aggregated amyloid-beta monoclonal antibody. The development follows the August 2024 approval for treating mild cognitive impairment (MCI) and mild dementia caused by Alzheimer’s

This collaboration is intended for the development of advanced biological signatures to improve targeted treatment strategies. It centres on leveraging BostonGene’s AI-powered omnimodal platform to analyse tumour molecular

The RMAT designation was based on initial data from March Bio’s ongoing multi-centre Phase II clinical trial, which indicated clinical activity and a manageable safety profile in a

The new site increases capacity and strengthens the company’s supply chain capabilities for RLTs in the US. The facility in Carlsbad, filed with the US Food and Drug

These candidates will be developed using SanegeneBio’s tissue-selective ligand and enhancer assisted delivery (LEAD) technology. The partnership focuses on advancing new therapies that can potentially be administered subcutaneously

The authorisations are granted for Gobivaz in 50 mg/0.5 mL and 100 mg/mL formulations, available in pre-filled syringes and autoinjectors. The medication is indicated for the treatment of

The designation highlights the considerable unmet medical needs of patients with AML and recognises LTI-214’s therapeutic potential as a new treatment for this aggressive form of blood cancer.

This agreement will involve the development and commercialisation of the anaesthetic intended for managing postoperative pain. The deal includes $5m upfront to AmacaThera and up to $225m in

CAL101 is intended for the treatment of idiopathic pulmonary fibrosis (IPF). It is currently studied in the Phase II AURORA trial, with patient recruitment underway in the US,